Stool transplants: Ready for prime time?

Current Gastroenterology Reports

Volumn 14, Issue 4, 2012, Pages 313-316

  Weissman, Jeffrey S ^a   Coyle, Walter ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

Clostridium difficile infection; Fecal microbiota transplant; Microbiota; Recurrent infection; Stool transplant

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; VANCOMYCIN;

ARTICLE; BACTERIAL TRANSMISSION; BIOLOGICAL THERAPY; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE INFECTION; COMPARATIVE EFFECTIVENESS; CONSTIPATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DONOR SELECTION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; ENTERITIS; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; INFECTION RISK; IRRITABLE COLON; MICROBIOME; NONHUMAN; PATHOGENESIS; PATIENT SAFETY; RECURRENCE RISK; RECURRENT INFECTION; RISK FACTOR; THERAPY EFFECT; TRANSPLANTATION; TREATMENT RESPONSE;

CLOSTRIDIUM DIFFICILE; DONOR SELECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; HUMANS; INTESTINES; METAGENOME; RECURRENCE;

EID: 84865653419     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-012-0263-7     Document Type: Article

References (20)

1. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010 May; 31(5):431-55. This article summarizes the rationale and recommendations for C. Difficile management from the Infectious Disease Society of America.
2. MillerMA, HylandM, Ofner-AgostiniM, et al. Morbidity, mortality and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Contr Hosp Epidemiol. 2002;23:137-40. (Pubitemid 34246541)
3. Miller MA, Gravel D, Mulvey M, et al. Surveillance for nosocomial Clostridium difficile associated diarrhea (N-CDAD) within acute-care hospitals in Canada: Results of the 2005 nosocomial infections surveillance program (CNISP) study shows escalating mortality. In: Proceedings of the 16th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America; March 18-21, 2006; Chicago, IL.
4. Olson MM, Shanholzer CJ, Lee Jr JT, et al. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Contr Hosp Epidemiol. 1994;15:271-381.
5. Kyne L, Hamel MB, Polavaram R, et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002; 34: 346-353 (Pubitemid 34062235)
6. O'Brien JA, Lahue BJ, Caro JJ, et al. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: Clinical and economic consequences. Infect Contr Hosp Epidemiol. 2007;28:1219-27. (Pubitemid 47596558)
7. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433-41. (Pubitemid 41770164)
8. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357(9251):189-93. (Pubitemid 32108091)
9. Surawicz C, Alexander J. Treatment of refractory and recurrent Clostridium difficile infection. J Nat Rev Gastroenterol Hepatol. 2011;8:330-9.
10. Arumugam M, Raes J, Pelletier et al. Enterotypes of the human gut microbiome. Nature. May (1473) 2011. 174-180.
11. Khanna S, Pardi D. The growing incidence and severity of C difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol. 2010;4(4):409-16.
12. Khoruts A, Dicksved J, Jansson JK, Sadowsky. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile associated diarrhea. J Clin Gastroenterol. 2010;44(5):354-60.
13. Enache-Angoulvant A, Hennequin C. Invasive Saccharomyces infection: A comprehensive review. Clin Infect Dis. 2005;41:1559-68. (Pubitemid 41691593)
14. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44(5):854-9.
15. Landy J, Al-Hassi HO, McLaughlin SD,Walker AW, Ciclitira PJ, Nicholls RJ, Clark SK, Hart AL. Review article: Faecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther. 2011 Aug; 34(4):409-15. This is an excellent review article summarizing the reported stool transplantations through early 2011.
16. Kelly CR, de Leon L, Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: Methodology and results. J Clin Gastroenterol. 2012;46(2):145-9.
17. Mattila E, Uusitalo-Seppälä R, Wuorela M et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology. 2011 Dec 7. [Epub ahead of print].
18. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized Frozen Preparation for Transplantation of Fecal Microbiota for Recurrent Clostridium difficile Infection. Am J Gastroenterol. 2012 Jan 31. [Epub ahead of print].
19. Brandt LJ, Borody TJ, Campbell J. Endoscopic fecal microbiota transplantation: "first-line" treatment for severe Clostridium difficile infection? J Clin Gastroenterol. 2011;45 (8):655-7.
20. Bakken JS, Borody T, Brandt LJ, Brill, JV, Demarco DC, Franzos MA, Kelly C, Khoruts A, Louie T, Martinelli LP, Moore TA, Russell G and Surawicz C. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011 Dec; 9 (12):1044-9. Written by the foremost authorities in stool transplantation, this paper provides a thorough review of the FMT literature and offers a protocol for sample preparation and administration.